ADvantage Therapeutics Reveals AD04TM's Immediate Effects in Alzheimer's Treatment

ADvantage Therapeutics has announced promising results from a recent study on AD04™, an innovative therapy for Alzheimer's disease. At the Alzheimer’s Association International Conference, the company presented a research poster titled "AD04™ - modifying Alzheimer’s disease by modulation of hippocampal lipid metabolism," showcasing the potential of this new treatment.

Key findings from the study highlighted the wide-ranging effects of AD04™, including immediate symptom relief and long-term disease modification. Clinical and proteomics-based studies demonstrated that AD04™ exhibits durable and multifaceted benefits. Notably, AD04™ has an excellent safety profile, as previous Phase 2 studies revealed that it does not cause ARIA-E/H, a common side effect associated with other Alzheimer’s treatments.

AD04™ operates by significantly restoring the expression of proteins involved in lipid metabolism in aged mice, bringing their levels in line with those of young mice. This restoration is believed to be a key factor in the therapeutic effects observed. Specifically, the treatment was found to upregulate important proteins in lipid metabolism, such as ACSL1, suggesting a strong link between the therapeutic benefits of AD04™ and the modulation of hippocampal lipid metabolism.

The clinical implications of these findings are significant. AD04™'s ability to modulate lipid metabolism and restore protein expression suggests potential improvements in cognitive function and overall brain health in Alzheimer’s patients. This could mark the advent of a new class of Alzheimer’s disease drugs, characterized by a unique mechanism of action and a favorable safety profile.

Dr. Carmela R. Abraham, Chief Scientific Officer of ADvantage Therapeutics, expressed optimism about the findings, stating that the significant and multifaceted benefits observed with AD04™ treatment represent a pivotal step forward in Alzheimer’s research. Dr. Abraham noted that AD04™ might offer a new lifeline to patients and their families by providing both immediate symptomatic relief and modification of the disease progression.

The research has been well-received by the scientific community, with anticipation building around upcoming clinical trials. ADvantage Therapeutics remains committed to advancing AD04™ through rigorous testing and regulatory review to bring a novel, effective, and safe treatment option to those affected by Alzheimer’s disease.

ADvantage Therapeutics is developing AD04™ as a new class of therapeutic for mild Alzheimer’s disease, exhibiting durable multifaceted effects. The compound has been extensively used as an adjuvant in human and animal vaccination programs. In previous trials, AD04™ serving as a control against another compound demonstrated statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups. It also showed slower decline in hippocampal volume as a biomarker.

The company believes that AD04™ may restore gene expression related to lipid metabolism, improve phagocytosis, and reduce inflammation, functioning as an immunomodulator to reduce Alzheimer’s pathology. Unlike treatments limited to specific aspects of Alzheimer’s pathology, such as amyloid beta or tau, AD04™ offers a more comprehensive approach.

Approximately fifty million people worldwide suffer from Alzheimer's Disease, which is a leading cause of death in industrialized countries. The World Health Organization estimated the global cost of dementia at $1.3 trillion in 2019, expected to rise to $2 trillion by 2030. The socio-economic burden of Alzheimer’s Disease is immense, devastating the lives of patients and their families. Currently, there are no approved disease-modifying drugs for Alzheimer’s, making the development of a safe, effective, and affordable treatment like AD04™ potentially transformative for patients.

ADvantage Therapeutics, headquartered in Miami, is focused on developing therapies for neurodegenerative conditions, particularly Alzheimer’s Disease. Their lead compound, AD04™, is under evaluation in confirmatory Phase 2b clinical trials in Europe, assessing its safety and efficacy in early Alzheimer's patients. The company is also exploring other approaches to combat neurodegenerative diseases, such as increasing levels of Klotho, a protein linked to longevity. ADvantage Therapeutics GmbH, based at the Vienna BioCenter, conducts early research and drug development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!